Macrophage extracellular traps promote maladaptive cardiac remodelling and heart failure via PAD4-dependent mechanisms

This study demonstrates that PAD4-dependent macrophage extracellular traps (METs) drive maladaptive cardiac remodeling and heart failure by promoting fibroblast activation, with clinical data showing that elevated MET levels correlate with worse cardiac function and survival in patients.

The Gist

The Big Picture: A Heart Under Siege

Imagine your heart as a busy, high-performance factory. When the factory gets too much pressure (like a clogged pipe or a heavy workload), the walls start to thicken, and the building begins to stretch out of shape. This is called heart failure.

For a long time, doctors knew that "firefighters" (immune cells) rushed into the factory to put out the fire caused by this stress. But they didn't realize that sometimes, these firefighters were accidentally setting new fires that made the building collapse faster.

This study discovered a specific, dangerous behavior of one type of firefighter: the Macrophage.

The Villain: "Macrophage Extracellular Traps" (METs)

Think of a macrophage as a security guard in your heart. Usually, they eat up trash and bacteria. But when they get too stressed, they do something drastic called "suicide by trap."

Instead of just eating the trash, they explode and shoot out a sticky, web-like net made of their own DNA and proteins. This is called a Macrophage Extracellular Trap (MET).

• The Analogy: Imagine a security guard, overwhelmed by stress, ripping out the factory's blueprints and throwing them all over the floor in a giant, sticky mess.
• The Problem: This "mess" isn't just garbage; it's toxic. It signals other workers in the factory to stop repairing the building and start building thick, hard walls (fibrosis) instead. This makes the heart stiff and unable to pump blood.

The Human Discovery: The "Sticky Mess" Predicts Trouble

The researchers looked at heart tissue samples from 69 patients with heart failure.

• What they found: Patients with the most "sticky mess" (METs) in their hearts had the worst outcomes. Their hearts were more stretched out, pumping less blood, and they were more likely to have a cardiac event (like death or needing a transplant).
• The Takeaway: The amount of this "sticky mess" in the heart tissue acts like a crystal ball. If a doctor sees a lot of METs, they know the patient is in serious trouble.

The Mouse Experiment: Cutting Off the Source

To figure out how to stop this, the scientists used mice. They created a model where the mice's hearts were under high pressure (like a tight band around the aorta).

1. The Trigger: They found that stressed heart cells (cardiomyocytes) were spitting out little bubbles called exophers. These bubbles were full of damaged mitochondria (the heart cell's batteries) and DNA.
2. The Reaction: When the security guards (macrophages) saw these bubbles, they panicked and created the sticky MET nets.
3. The Key Ingredient: The study found that a specific enzyme called PAD4 was the "switch" that turned the macrophages into net-shooters. Without PAD4, the guards stayed calm and didn't make the sticky mess.

The Solution:
The researchers took bone marrow (where immune cells are born) from mice that lacked the PAD4 enzyme and transplanted it into normal mice.

• Result: When these "super mice" had their hearts stressed, they didn't make the sticky nets. Their hearts stayed stronger, didn't get as stiff, and the mice lived longer.

The Mechanism: How the Trap Hurts the Heart

The study also figured out exactly how the sticky nets damage the heart.

• The nets contain a specific protein (citrullinated histone) that acts like a false alarm siren.
• This siren rings a bell on the heart's "construction workers" (fibroblasts).
• The construction workers hear the siren and think, "Oh no, we need to build a fortress!" So, they start laying down thick scar tissue (fibrosis) instead of fixing the muscle.
• The Fix: The researchers found that if they blocked the "siren" (using a TLR4 inhibitor), the construction workers stopped over-building, and the heart stayed healthy.

The Conclusion: A New Way to Treat Heart Failure

This paper tells us a new story about heart failure:

1. The Cause: Stressed heart cells spit out "bad bubbles" (exophers).
2. The Reaction: Immune cells (macrophages) see these bubbles and panic, shooting out toxic DNA nets (METs) using a switch called PAD4.
3. The Damage: These nets trick the heart into building stiff scar tissue, leading to heart failure.
4. The Cure: If we can find a drug to turn off the PAD4 switch or block the siren (TLR4), we might be able to stop the heart from turning into a stiff, scarred brick wall.

In short: The heart isn't just failing because it's tired; it's failing because its own immune system is accidentally shooting itself in the foot with sticky DNA nets. Stopping those nets could save lives.

Technical Summary

1. Problem Statement

Heart failure (HF) is characterized by maladaptive cardiac remodeling involving hypertrophy, fibrosis, and dilation, driven largely by chronic inflammation. While the role of neutrophil extracellular traps (NETs) in cardiovascular disease is established, the presence, clinical relevance, and mechanistic role of Macrophage Extracellular Traps (METs) in heart failure remain unknown. Furthermore, the specific molecular drivers of MET formation in the failing heart and their downstream effects on cardiac fibroblasts are poorly understood. This study aims to elucidate the role of METs in HF pathogenesis and identify potential therapeutic targets.

2. Methodology

The study employed a multi-modal approach combining clinical human data, murine models, and in vitro mechanistic experiments:

• Clinical Cohort:

  • Subjects: 69 patients with symptomatic Heart Failure with reduced Ejection Fraction (HFrEF) due to idiopathic dilated cardiomyopathy who underwent endomyocardial biopsy.
  • Controls: 10 age- and sex-matched subjects without heart failure.
  • Analysis: Fluorescent immunohistochemistry was used to identify METs (defined as Citrullinated Histone H3+ / CD68+ / Troponin I- structures). MET counts were correlated with echocardiographic parameters and clinical outcomes (composite of cardiac death, worsening HF, or LVAD implantation).

• Murine Models:

  • Pressure Overload: Transverse Aortic Constriction (TAC) was performed on Wild-Type (WT) mice to induce HFrEF.
  • Genetic Manipulation: Bone Marrow Transplantation (BMT) was used to create chimeric mice. Recipient WT mice were transplanted with bone marrow from either WT or PAD4 Knockout (PAD4KO) mice. This isolates the role of hematopoietic PAD4.
  • Neutrophil Depletion: Anti-Ly6G antibodies were administered to distinguish the contributions of NETs vs. METs.
  • Cell Sorting: Cardiomyocyte-specific tdTomato reporter mice were used to isolate exophers (large subcellular vesicles) via FACS.

• In Vitro Mechanisms:

  • Cell Lines: Bone Marrow-Derived Macrophages (BMDMs) from WT and PAD4KO mice; RAW264.7 cells; Primary Cardiac Fibroblasts.
  • Triggers: Stimulation with mitochondrial DNA (mtDNA), nuclear DNA, and isolated cardiac exophers.
  • Inhibitors: PAD4 inhibitor (GSK484) and TLR4 inhibitor (TLR4-IN-C34).
  • Proteomics: LC-MS/MS was used to profile the protein composition of METs.

3. Key Contributions

• First Clinical Evidence: Demonstrated that METs are abundant in the myocardium of HFrEF patients and serve as a novel tissue biomarker for adverse remodeling and poor prognosis.
• Mechanistic Discovery: Identified mitochondrial DNA (mtDNA)-enriched exophers released by stressed cardiomyocytes as the primary trigger for MET formation.
• Pathway Elucidation: Established the PAD4-dependent mechanism for MET formation and the subsequent TLR4-mediated activation of cardiac fibroblasts leading to fibrosis.
• Therapeutic Target: Validated that hematopoietic PAD4 deficiency protects against cardiac remodeling, suggesting PAD4 inhibition as a viable therapeutic strategy.

4. Key Results

A. Clinical Findings (Human Data)

• MET Presence: METs were significantly more abundant in HFrEF patient biopsies compared to controls.
• Correlations: MET counts negatively correlated with Left Ventricular Ejection Fraction (LVEF) and positively correlated with Left Ventricular End-Diastolic Diameter (LVEDD).
• Prognosis: Patients with high MET counts (>2.69 METs/mm²) had significantly lower event-free survival and a higher risk of composite cardiac events (death, worsening HF, LVAD) compared to those with low counts.

B. In Vivo Murine Models

• Temporal Dynamics: In TAC mice, METs appeared as early as 1 day post-surgery, peaked at 3 days, and persisted for 4 weeks.
• PAD4 Role:
  • PAD4KO-BMT Mice: Mice receiving bone marrow from PAD4KO donors showed preserved LVEF, reduced LV dilation, lower lung weight (less congestion), and significantly improved survival compared to WT-BMT mice after TAC.
  • Fibrosis: PAD4KO-BMT mice exhibited significantly reduced myocardial fibrosis and lower expression of fibrosis markers (Collagen III, BNP).
  • MET Suppression: PAD4 deficiency in bone marrow cells completely suppressed MET formation in the myocardium during both early and late phases of pressure overload.
• Neutrophil Independence: Depleting neutrophils (anti-Ly6G) improved cardiac function in WT mice but did not abolish the protective effect seen in PAD4KO mice. This confirms that METs (macrophage-derived) contribute to HF pathology independently of NETs (neutrophil-derived).

C. Molecular Mechanisms

• Trigger Identification:
  • Exophers: Isolated cardiomyocyte-derived exophers were rich in mitochondria and mtDNA.
  • Induction: Administration of these exophers (or purified mtDNA) induced robust MET formation in WT BMDMs, but not in PAD4KO BMDMs.
  • Specificity: Nuclear DNA failed to induce METs, highlighting the specificity of mtDNA as the trigger.
• Downstream Effects:
  • Proteomics: METs contained histones (H1-H4) and 47 unique proteins not found in NETs.
  • Fibroblast Activation: Conditioned medium from MET-inducing macrophages induced the transition of cardiac fibroblasts to myofibroblasts (increased $\alpha$-SMA).
  • Signaling Pathway: This activation was mediated by TLR4 signaling, as TLR4 inhibition blocked the fibroblast transition.

5. Significance and Translational Perspective

• Novel Pathogenic Driver: The study identifies METs as a distinct and critical driver of maladaptive cardiac remodeling, separate from NETs.
• Biomarker Potential: Myocardial MET burden could serve as a tissue biomarker to improve risk stratification in HFrEF patients.
• Therapeutic Strategy: The findings suggest a dual-target therapeutic approach:
  1. PAD4 Inhibition: To prevent MET formation at the source (macrophages).
  2. TLR4 Inhibition: To block the downstream fibrotic signaling in cardiac fibroblasts.
• Cell-Cell Communication: The study highlights a critical "cardiomyocyte-to-macrophage-to-fibroblast" axis where stressed cardiomyocytes release exophers (mtDNA), triggering macrophages to release METs, which in turn drive fibrosis.

Conclusion: PAD4-dependent MET formation is a novel, hematopoietic-driven mechanism that exacerbates heart failure. Targeting this pathway offers a promising strategy to attenuate cardiac fibrosis and improve outcomes in heart failure patients.